Active ingredients: cefepime
What it is used for
Adults: DBL Cefepime Powder for injection is indicated in the treatment of the infections listed below when caused by susceptible bacteria: Lower respiratory tract infections, including pneumonia and bronchitis, Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections, Skin and skin structure infections, Intra-abdominal infections, including peritonitis and biliary tract infections, Gynaecological infections, Septicaemia, Empiric treatment in febrile neutropenic patients (See Precautions). DBL Cefepime Powder for injection is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. In this indication it is essential that metronidazole also be administered. Paediatrics: DBL Cefepime Powder for injection is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused be susceptible bacteria: Pneumonia, Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections, Skin and skin structure infections, Septicaemia, Empiric treatment in febrile neutropenic patients (See Precautions). Culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. Empiric therapy with DBL Cefepime Powder for injection may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative bacteria, DBL Cefepime Powder for injection can be used appropriately as monotherapy prior to identification of the causative organism(s). In the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with DBL Cefepime Powder for injection. In patients who are at risk of mixed aerobic-anaerobic infection, including infections in which Bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.
How to take it
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
- Store below 25 degrees Celsius
- Protect from Light
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
White to pale yellow powder
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient cefepime
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems